Skip to main content
. 2023 Aug 28;6(8):e2329066. doi: 10.1001/jamanetworkopen.2023.29066

Figure 2. Observed and Projected Low-Density Lipoprotein Cholesterol (LDL-C) Trajectories.

Figure 2.

The mean LDL-C levels and 95% CIs for observed lipid-lowering therapy are presented, along with those projected for an optimized statin regimen alone and for an optimized statin regimen with ezetimibe. Compared with observed LDL-C levels, optimized statin treatment was associated with a 21.9 mg/dL (to convert to millimoles per liter, multiply by 0.0259) projected reduction at 1 year and a 23.0 mg/dL projected reduction at 3 years. Compared with optimized statin therapy alone, the addition of ezetimibe was associated with an additional 8.7 mg/dL projected LDL-C value reduction at both 1 and 3 years, corresponding to 30.6 mg/dL and 31.7 mg/dL reductions from observed levels. Thus, the addition of ezetimibe to an optimized statin regimen resulted in a further 39.7% and 37.8% reduction of LDL-C levels of the reductions achieved by optimized statin alone at 1 and 3 years, respectively.